BRAF and Alzheimer disease: Rhabdomyolysis is an adverse effect of trametinib that has been seen in less than 10% of participants in the METRIC study, less than 10% of participants in the COMBI-d study (combined with dabrafenib, a BRAF inhibitor), and less than 1% of participants in the COMBI-AD Study (31).